IQVIA (NYSE:IQV) PT Lowered to $265.00 at Evercore ISI

IQVIA (NYSE:IQV) had its price objective lowered by Evercore ISI from $270.00 to $265.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Evercore ISI currently has an outperform rating on the medical research company’s stock.

Several other analysts also recently weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the company an overweight rating in a research report on Monday, August 5th. Argus raised shares of IQVIA to a strong-buy rating in a research note on Wednesday, July 31st. Royal Bank of Canada assumed coverage on shares of IQVIA in a research note on Wednesday, September 4th. They set an outperform rating and a $275.00 target price for the company. Morgan Stanley upped their price target on IQVIA from $270.00 to $280.00 and gave the company an overweight rating in a report on Tuesday, July 23rd. Finally, Truist Financial raised their price objective on IQVIA from $292.00 to $300.00 and gave the stock a buy rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $269.36.

IQVIA Trading Up 0.6 %

NYSE:IQV opened at $230.24 on Tuesday. IQVIA has a one year low of $167.42 and a one year high of $261.73. The business’s 50-day simple moving average is $239.78 and its 200 day simple moving average is $232.00. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The stock has a market cap of $41.97 billion, a price-to-earnings ratio of 29.90, a price-to-earnings-growth ratio of 2.18 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the prior year, the business posted $2.22 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that IQVIA will post 10.25 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently added to or reduced their stakes in IQV. Park Place Capital Corp bought a new stake in shares of IQVIA during the third quarter worth approximately $28,000. Rise Advisors LLC bought a new stake in IQVIA in the 1st quarter valued at $31,000. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co bought a new position in IQVIA during the 1st quarter worth $32,000. Finally, Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA during the second quarter worth $27,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.